Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $165.83 +2.72%
Revenue Growth %: +26.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +26.4%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.65, $0.69 better than the analyst estimate of $0.96. Revenue for the quarter came in at $687.5 million versus the consensus estimate of $653.32 million.
GUIDANCE:
Neurocrine Biosciences sees FY2025 revenue of $2.5-2.55 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chemours reaches $450M settlement over PFAS pollution at four sites
- Palantir (PLTR) call put ratio 1.8 calls to 1 put with a focus on June 127, 129 and 132 calls
- NVIDIA (NVDA) spreader of 10K contracts of July and October 220 calls
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
